ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "PD-1 and adverse events"

  • Abstract Number: 1173 • ACR/ARHP Annual Meeting 2017

    Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort

    David Liew1,2,3, Jessica Leung1, Bonnia Liu1, Jonathan Cebon3,4, Albert Frauman2,3 and Russell Buchanan1, 1Department of Rheumatology, Austin Health, Melbourne, Australia, 2Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, 3Department of Medicine, University of Melbourne, Melbourne, Australia, 4Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia

    Background/Purpose: Immune checkpoint therapy with programmed cell death protein 1 (PD-1) inhibitors has led to significant survival benefits in the treatment of multiple cancers. This…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology